Keyphrases
Acute Leukemia
11%
Acute Lymphoblastic Leukemia
11%
Acute Myeloid Leukemia
26%
Adrenoleukodystrophy
6%
Allogeneic
8%
Allogeneic Bone Marrow Transplantation
7%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
65%
Allogeneic Transplantation
9%
B Cells
6%
Bone Marrow
13%
Bone Marrow Transplantation
20%
Cell Therapy
13%
Chemotherapy
10%
Children's Oncology Group
9%
Chimeric Antigen Receptor T Cells (CAR-T)
5%
Chronic Myeloid Leukemia
6%
Clinical Outcomes
8%
Clinical Trials
11%
Conditioning Regimen
6%
Confidence Interval
26%
COVID-19
6%
Critically Ill children
6%
Cyclophosphamide
7%
Cytomegalovirus
6%
Disease-free Survival
5%
Donor T Cell
5%
Electronic Health Records
7%
Embryonic Stem Cells
6%
Endothelial Cells
5%
Engraftment
10%
Epidermolysis Bullosa
9%
Fanconi Anemia
9%
First Complete Remission
6%
Fludarabine
6%
Graft-versus-host Disease (GvHD)
100%
Graft-versus-leukemia Effect
6%
Hazard Ratio
11%
Hematological Malignancies
9%
Hematopoietic Cell Transplant
10%
Hematopoietic Cell Transplantation
44%
Hematopoietic Stem Cell Transplantation
21%
Hematopoietic Stem Cells
12%
High Risk
8%
HLA Matching
8%
HLA-matched Donor
6%
Hurler Syndrome
5%
Induced Pluripotent Stem Cells (iPSCs)
11%
Inflammation
6%
Interleukin-15 (IL-15)
8%
Interleukin-2
8%
Killer Cell Immunoglobulin-like Receptor
8%
Leukemia
9%
Leukemia Patients
6%
Lymphoma
6%
Marrow
8%
Marrow Transplantation
23%
Mesenchymal Stromal Cells
7%
Mouse Model
7%
Myeloablative
7%
Myeloablative Conditioning
8%
Myelodysplastic Syndrome
8%
Myogenic Progenitors
6%
Natural Killer Cells
41%
Non-relapse Mortality
8%
Older Adults
6%
Ovarian Cancer
5%
Overall Survival
19%
Pediatric
12%
Pediatric Patients
8%
Peripheral Blood
6%
Pharmacokinetics
5%
Phase II Trial
5%
Photosystem II
10%
Platelets
5%
Pretransplant
9%
Progression-free Survival
6%
Reduced-intensity Conditioning
14%
Regulatory T Cells
12%
Relapsed or Refractory
8%
Relative Risk
6%
Risk Factors
8%
Sickle Cell Disease
11%
Stem Cell Transplantation
5%
Stem Cell-derived
7%
Stem Cells
6%
Survivors
9%
T Cell Activation
5%
T Cells
22%
Tacrolimus
6%
Total Body Irradiation
6%
Transfusion
7%
Transplant Outcomes
10%
Transplantation
34%
Treg
13%
Tumor
8%
Umbilical Cord Blood
22%
Umbilical Cord Blood Transplantation
16%
United States
6%
Unrelated Donor
28%
Unrelated Donor Transplantation
8%
Medicine and Dentistry
Acute Graft Versus Host Disease
14%
Acute Leukemia
8%
Acute Lymphoblastic Leukemia
12%
Acute Myeloid Leukemia
21%
Allogeneic Hematopoietic Stem Cell Transplantation
8%
Allograft
5%
Allotransplantation
8%
B Cell
6%
Biological Marker
7%
Bone Marrow Transplantation
18%
Cell Therapy
13%
Cell Transplantation
56%
Chronic Graft Versus Host Disease
22%
Clinical Trial
12%
Conditioning
8%
Cord Blood
22%
Cord Blood Stem Cell Transplantation
9%
COVID-19
5%
Cyclophosphamide
6%
Disease
34%
Engraftment
7%
Epidermolysis Bullosa Dystrophica
5%
Fanconi Anemia
7%
Graft Versus Host Reaction
31%
Hazard Ratio
10%
Hematologic Malignancy
7%
Hematopoietic Stem Cell
67%
Hematopoietic Stem Cell
7%
Hematopoietic Stem Cell Transplantation
20%
Hurler Syndrome
9%
Immunotherapy
6%
In Vitro
8%
Induced Pluripotent Stem Cell
5%
Infection
12%
Infusion
5%
Leukemia
11%
Malignant Neoplasm
12%
Medicine
5%
Mesenchymal Stem Cell
6%
Multiple Myeloma
5%
Myelodysplastic Syndrome
9%
Natural Killer Cell
16%
Neoplasm
11%
Oncology
10%
Ovarian Cancer
7%
Overall Survival
19%
Pediatrics
20%
Pediatrics Patient
5%
Platelet
8%
Progression Free Survival
6%
Reduced Intensity Conditioning
9%
Regulatory T Cell
6%
Sickle-Cell Disease
9%
Stem Cell
8%
T Cell
19%
Transplantation
53%
Whole Body Radiation
5%
Immunology and Microbiology
Acute Graft Versus Host Disease
28%
Allele
5%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Allotransplantation
8%
B Cell
13%
Blood Plasma
5%
Bone Marrow Transplantation
13%
CD34
5%
CD4
5%
Cell Function
7%
Cell Transplantation
54%
Chronic Graft Versus Host Disease
29%
Conditioning
24%
Cord Blood Stem Cell Transplantation
16%
Cyclophosphamide
9%
Cytokine
9%
Cytomegalovirus
8%
Cytotoxic T-Cell
6%
Disease Free Survival
5%
Engraftment
11%
Graft-Versus-Host Disease
57%
Hematopoietic Cell
62%
Hematopoietic Stem Cell
10%
Hematopoietic Stem Cell Transplantation
17%
Human Leukocyte Antigen
5%
Immunotherapy
8%
Interleukin 15
6%
Killer-Cell Immunoglobulin-Like Receptor
6%
Lineages
7%
Lymphocyte
5%
Mesenchymal Stem Cell
8%
Mouse
26%
Myeloid
19%
Natural Killer Cell
42%
Neutrophil
6%
Overall Survival
14%
Platelet
6%
Regulatory T Cell
25%
Stem Cell
9%
T Cell
38%
T-Helper Cell
7%
Tacrolimus
6%
Transplant Procedure
50%
Umbilical Cord Blood
31%